Molecular Quality Controls Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Molecular Quality Controls Market Dynamics

Growing Adoption of Multiplexed Quality Control Materials Is a Key Trend

• The molecular quality control market is evolving toward high-end solutions as multiplexed quality control materials become an emerging market trend. The expanding molecular diagnostic testing operations in laboratories have rendered traditional single-analyte controls less efficient to monitor results effectively.
• Multiplexed quality controls improve laboratory efficiency by allowing laboratories to validate many genetic markers and pathogens through a single unified assay. The shift in molecular diagnostics towards high-throughput technologies along with comprehensive testing panels drives this trend.
• Laboratories pursue efficiency-based workflows so multiplexed quality controls match this direction by cutting down assessment quality costs and time and variability.
• These controls have become more attractive to meet regulatory requirements because quality management systems receive increased emphasis from regulatory agencies.
• Laboratory diagnostics will be shaped by the increasing demand for precise medicine tests and screening of infectious diseases alongside genetic screening which will boost the usage of multiplexed quality control materials.

Rising Number of Accredited Clinical Laboratories Are the Growth Driver

• The rising number of accredited clinical laboratories serves as a main growth factor within the molecular quality controls industry. Laboratories across the world seek accreditation because diagnostic testing demands continue escalating while standards for quality and regulation become more demanding.
• Academic accreditation transformed from an optional requirement into a mandatory standard because it helps laboratories achieve national and international guidelines while improving their credibility and delivering better patient results.
• The world faces rising disease burdens from cancer and infectious diseases and genetic disorders that have sparked a testing diagnostic demand increase worldwide.
• Laboratories need to establish strong quality control systems to uphold their standards thereby increasing their requirement for molecular quality control products.
• The drive for laboratories toward accreditation has intensified because healthcare organizations along with regulatory bodies stress the necessity of standardized testing.
• Laboratory accreditation stands as a driving force behind market expansion because the increasing need for molecular quality controls from testing facilities aiming to comply with standards.

Molecular Quality Controls Market Segmentation and Category Analysis

Product Type Analysis

The independent controls category held the larger market share, of 75%, in 2024. The market demonstrates a preference for third-party controls because they offer objective diagnostic test performance evaluation and support multiple instrumentation platforms with regulatory-compliant requirements. The growing number of accredited laboratories together with regulatory body regulations strongly promotes their widespread adoption. The instrument-specific controls category will grow at a higher CAGR, during the forecast period. Genomic research together with decreasing sequencing costs and expanding NGS applications in personalized medicine and oncology drives this rapid market growth. The increased role of NGS in clinical diagnostics produces rapid growth for specialized quality controls needed to maintain result accuracy and reliability.

The product types analyzed here are:

• Independent Controls (Larger Category)
• Instrument-Specific Controls (Faster-Growing Category)
  • PCR
  • DNA sequencing & NGS

Analyte Type Analysis

The single-analyte category held the larger market share, of 70%, in 2024, because they are widely utilized in standard diagnostic tests. Single-analyte controls serve as critical tools for laboratories to check the precision of single biomarkers which are necessary for specific molecular tests such as infectious disease and genetic mutation and cancer marker detection. Their regulatory approval together with convenient operational characteristics and precise single-target assay tracking makes them maintain their market leadership position.

The multi-analyte category will grow at a higher CAGR, during the forecast period. This is because medical laboratories implement high-throughput testing technologies and multiplex methods. Single assay procedures can use these controls to validate multiple biomarkers simultaneously thus providing both cost efficiency and laboratory performance enhancement. Clinical and research laboratories adopt multi-analyte controls at an accelerated rate because of rising demands for genetic screening and NGS and multiplex PCR applications.

The analyte types analyzed here are:

• Single-Analyte (Larger Category)
• Multi-Analyte (Faster-Growing Category)

Application Analysis

The infectious disease diagnosis category held the largest market share, of 60%, in 2024, because infections including respiratory illnesses and sexually transmitted diseases and HIV/AIDS as well as hepatitis have been expanding internationally. The accurate and reliable detection of early conditions depends on molecular diagnostic tests which need to be supported by strict quality control systems for reliable test outcomes. Quality control measures in infectious disease diagnostics gained more importance because of the COVID-19 pandemic which resulted in enhanced molecular testing adoption.

The oncology testing category will grow at a highest CAGR, during the forecast period. The increasing cancer global prevalence together with personal medicine strategies that need molecular diagnostic analysis for targeted biomarker identification drive this sector's rapid expansion. The precision of cancer diagnosis through next-generation sequencing (NGS) technology requires specialized quality controls to ensure test accuracy and reliability because of its growing demand. The segment grows rapidly because public awareness leads to increased screening programs for early cancer detection.

The applications analyzed here are:

• Infectious Disease Diagnosis (Largest Category)
• Oncology Testing (Fastest-Growing Category)
• Genetic Testing

End User Analysis

The diagnostic laboratories category held the largest market share, of 65%, in 2024. The laboratories conducting molecular diagnostic examinations perform large test volumes for infectious disease screening together with oncology biomarker detection and genetic testing. Accredited laboratories combined with strict quality control requirements and expanding third-party quality control needs drive laboratories to maintain their position as market leaders. The market leadership of the company increases through the growth of laboratory networks and increased outsourcing of molecular testing services.

The IVD kit manufacturers & CROs category will grow at a highest CAGR, during the forecast period. The expanding molecular diagnostic market requirements have triggered an escalation in in-vitro diagnostic (IVD) kit and assay development which requires strong quality control procedures. The expansion of CROs that perform clinical research and regulatory compliance testing combined with their vital role increases the demand for molecular quality controls. The segment experiences fast growth due to rising diagnostic company research institutions and pharmaceutical firm cooperation relationships.

The end users analyzed here are:

• Diagnostic Laboratories (Largest Category)
• Hospitals
• IVD Kit Manufacturers & CROs (Fastest-Growing Category)
• Academic and Research Institutes

Molecular Quality Controls Market Geographical Analysis

The North America held the largest market share, of 45%, in 2024, because of its established healthcare system together with advanced molecular diagnostic technology and strict regulatory standards. The region’s market dominance stems from increased genomic research funding by the government and rising numbers of accredited clinical laboratories together with the high prevalence of diseases that need molecular diagnostics testing. The U.S., in particular, leads with advanced laboratory facilities and high healthcare expenditure.

The Europe will grow at a highest CAGR, during the forecast period. This is because governments back precision medicine through their funding and provide regulatory requirements for laboratory quality assurance as technology advances within diagnostic instruments. The market demand for molecular diagnostics and genomic research increases rapidly in Germany as well as the United Kingdom and France where substantial funding takes place. The increasing number of accredited laboratories and rising infectious diseases and cancer cases drive rapid growth for molecular quality control products throughout the region. The European market grows further because research institutions align with healthcare organizations to enhance market advancement.

The regions analyzed in this report are:

• North America (Largest Region)
  • U.S.
  • Canada
• Europe (Fastest-Growing Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Molecular Quality Controls Market Share Analysis

The molecular quality control market shows fragmentation because multiple global and regional businesses defend their market position. Specialized companies enter the market because of rising diagnostic testing requirements thus developing novel quality control solutions for accurate diagnoses. Companies establish their position through technological leadership and regulatory commitment along with strategic business alliances. The company Thermo Fisher Scientific stands as the dominant leader due to its broad product range and worldwide market presence. The market includes clinical laboratories and research institutions as well as diagnostic companies because of three key factors: precision medicine development needs and regulatory compliance requirements and growing molecular diagnostic usage for disease management and genetic tests.

Molecular Quality Controls Market Developments

• In February 2025, Bio-Rad announced its intention to acquire Stilla Technologies, a leading developer of digital PCR technology. This move aims to strengthen Bio-Rad’s position in molecular diagnostics and expand its offerings in precision medicine. The acquisition will enhance capabilities in genetic analysis and high-sensitivity testing.
• In December 2024, LGC acquired DiaMex to enhance innovation and expand its molecular and serology quality control offerings for clinical laboratories. This acquisition strengthens LGC’s position in providing high-quality diagnostic solutions to meet growing laboratory demands. The move aligns with LGC’s strategy to improve choice and efficiency for core lab customers.